Imatinib
Brand: Gleevec (US/EU) / Imatinib (IN/BD)
Anticancer
BCR-ABL Tyrosine Kinase Inhibitor
Pharmacokinetics
| Half-life | 18 hours |
| Tmax | 2.5 h |
| Bioavailability | 98 % (approx) |
| Protein Binding | 95 % |
| Volume of Distribution | 4.9 L/kg (approx) |
| Clearance Route | hepatic |
| Active Metabolites | yes |
| Notes | CYP3A4 metabolism. Standard dose 400 mg/day; max 800 mg/day in accelerated/blast phase CML. |
⚠️ Safety & Warnings
Severity: Moderate
Adverse Effects:
Fluid retention, edema, N/V, rash, cytopenias
Contraindications:
Severe hepatic impairment
Precautions:
Monitor CBC, liver enzymes; edema may need diuretics